1.Protective effect of platelet-rich plasma against structural and functional changes of the adult rat testis in carbimazole-induced hypothyroidism
Hossein BORDBAR ; Masoud SATTAR-SHAMSABADI ; Farzaneh DEHGHANI ; Fatemeh KARIMI
Clinical and Experimental Reproductive Medicine 2024;51(3):225-235
Objective:
Hypothyroidism (HT) influences spermatogenesis and is associated with male infertility. Platelet-rich plasma (PRP), a biological product rich in growth factors, promotes tissue repair. In this study, the likely protective effects of PRP on testicular tissue damage in carbimazole (CBZ)-induced HT were evaluated.
Methods:
Forty male rats were divided into four groups. HT was induced by administering CBZ (1.35 mg/kg orally, for 45 days). Two doses of PRP (40 μL each, locally injected into the testis on days 15 and 30) were also given. After 45 days, blood samples were taken from the heart to measure triiodothyronine (T3), thyroxine (T4), and testosterone levels, and semen analysis was performed. For stereological assessment, the left testis was removed, fixed, embedded, sectioned, and stained with hematoxylin and eosin. The right testis was excised to evaluate antioxidant levels.
Results:
CBZ was demonstrated to induce HT, characterized by significant reductions in T3 and T4. HT was associated with decreased testicular weight, impaired sperm parameters, reduced testosterone concentration, diminished antioxidant activity, reduced volumes of testicular components, and lower total numbers of testicular cells of various types. When HT samples were treated with PRP, improvement was observed for all of these changes. This protective effect could be attributed to the growth factors present in PRP.
Conclusion
PRP appears to prevent the structural changes in the testes and the deterioration in sperm quality caused by CBZ-induced HT. This protective effect is likely due to mitigation of oxidative damage and elevation of testosterone levels.
2.Correction: Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation
Omid Reza ZEKAVAT ; Yasaman MOVAHEDNEZHAD ; Amin SHAHSAVANI ; Sezaneh HAGHPANAH ; Negin SHOKRGOZAR ; Hossein GOLMOGHADDAM ; Mehdi KALANI ; Mohammad Reza BORDBAR ; Nargess ARANDI
Blood Research 2024;59():17-
3.Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation
Omid Reza ZEKAVAT ; Yasaman MOVAHEDNEZHAD ; Amin SHAHSAVANI ; Sezaneh HAGHPANAH ; Negin SHOKRGOZAR ; Hossein GOLMOGHADDAM ; Mehdi KALANI ; Mohammad Reza BORDBAR ; Nargess ARANDI
Blood Research 2024;59():16-
Background:
Development of antibodies against infused Factor VIII (FVIII) or "inhibitors" represents a major challenge following FVIII replacement therapy in patients with hemophilia A (HA). Recent studies have shown that certain cellular compartments of the immune system contribute to the production of such antibodies. Herein, we determined the frequency of class-switched CD19+IgD−CD27+ on-class-switched CD19+IgD+CD27+ memory B cell subsets and CD19 + CD27hiCD38hi plasmablasts in patients with severe HA and their association with the development of inhibitors in these patients.
Methods:
This cross-sectional case–control study enrolled 32 patients with severe HA, including 8 with and 24 without inhibitors, and 24 healthy individuals. The frequencies of the memory B cell subsets and plasmablasts were determined using flow cytometry.
Results:
The frequency of CD19+IgD+CD27+ non-class-switched memory B cells was significantly lower in patients with HA (including both patients with and without inhibitors) than in healthy controls. The percentages of both CD19+IgD−CD27+ class-switched and CD19+IgD+CD27+ non-class-switched memory B cells did not differ significantly between patients with and without inhibitors. HA patients with inhibitors had significantly higher proportions of CD19+CD27hiCD38hi plasmablasts than the control group as well as the inhibitor (-) ones. No significant correlation was observed between the inhibitor levels with the percentages of memory B cell subsets and plasmablasts.
Conclusion
This study is the first to demonstrate a dysregulated proportion of CD19+IgD+CD27+ non-class-switched memory B cells and CD19+CD27hiCD38hi plasmablasts in patients with severe HA. Therefore, strategies targeting memory B-cell/plasmablast differentiation may have promising outcomes in the management of inhibitor formation in patients with severe HA.
4.Correction: Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation
Omid Reza ZEKAVAT ; Yasaman MOVAHEDNEZHAD ; Amin SHAHSAVANI ; Sezaneh HAGHPANAH ; Negin SHOKRGOZAR ; Hossein GOLMOGHADDAM ; Mehdi KALANI ; Mohammad Reza BORDBAR ; Nargess ARANDI
Blood Research 2024;59():17-
5.Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation
Omid Reza ZEKAVAT ; Yasaman MOVAHEDNEZHAD ; Amin SHAHSAVANI ; Sezaneh HAGHPANAH ; Negin SHOKRGOZAR ; Hossein GOLMOGHADDAM ; Mehdi KALANI ; Mohammad Reza BORDBAR ; Nargess ARANDI
Blood Research 2024;59():16-
Background:
Development of antibodies against infused Factor VIII (FVIII) or "inhibitors" represents a major challenge following FVIII replacement therapy in patients with hemophilia A (HA). Recent studies have shown that certain cellular compartments of the immune system contribute to the production of such antibodies. Herein, we determined the frequency of class-switched CD19+IgD−CD27+ on-class-switched CD19+IgD+CD27+ memory B cell subsets and CD19 + CD27hiCD38hi plasmablasts in patients with severe HA and their association with the development of inhibitors in these patients.
Methods:
This cross-sectional case–control study enrolled 32 patients with severe HA, including 8 with and 24 without inhibitors, and 24 healthy individuals. The frequencies of the memory B cell subsets and plasmablasts were determined using flow cytometry.
Results:
The frequency of CD19+IgD+CD27+ non-class-switched memory B cells was significantly lower in patients with HA (including both patients with and without inhibitors) than in healthy controls. The percentages of both CD19+IgD−CD27+ class-switched and CD19+IgD+CD27+ non-class-switched memory B cells did not differ significantly between patients with and without inhibitors. HA patients with inhibitors had significantly higher proportions of CD19+CD27hiCD38hi plasmablasts than the control group as well as the inhibitor (-) ones. No significant correlation was observed between the inhibitor levels with the percentages of memory B cell subsets and plasmablasts.
Conclusion
This study is the first to demonstrate a dysregulated proportion of CD19+IgD+CD27+ non-class-switched memory B cells and CD19+CD27hiCD38hi plasmablasts in patients with severe HA. Therefore, strategies targeting memory B-cell/plasmablast differentiation may have promising outcomes in the management of inhibitor formation in patients with severe HA.
6.Correction: Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation
Omid Reza ZEKAVAT ; Yasaman MOVAHEDNEZHAD ; Amin SHAHSAVANI ; Sezaneh HAGHPANAH ; Negin SHOKRGOZAR ; Hossein GOLMOGHADDAM ; Mehdi KALANI ; Mohammad Reza BORDBAR ; Nargess ARANDI
Blood Research 2024;59():17-
7.Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation
Omid Reza ZEKAVAT ; Yasaman MOVAHEDNEZHAD ; Amin SHAHSAVANI ; Sezaneh HAGHPANAH ; Negin SHOKRGOZAR ; Hossein GOLMOGHADDAM ; Mehdi KALANI ; Mohammad Reza BORDBAR ; Nargess ARANDI
Blood Research 2024;59():16-
Background:
Development of antibodies against infused Factor VIII (FVIII) or "inhibitors" represents a major challenge following FVIII replacement therapy in patients with hemophilia A (HA). Recent studies have shown that certain cellular compartments of the immune system contribute to the production of such antibodies. Herein, we determined the frequency of class-switched CD19+IgD−CD27+ on-class-switched CD19+IgD+CD27+ memory B cell subsets and CD19 + CD27hiCD38hi plasmablasts in patients with severe HA and their association with the development of inhibitors in these patients.
Methods:
This cross-sectional case–control study enrolled 32 patients with severe HA, including 8 with and 24 without inhibitors, and 24 healthy individuals. The frequencies of the memory B cell subsets and plasmablasts were determined using flow cytometry.
Results:
The frequency of CD19+IgD+CD27+ non-class-switched memory B cells was significantly lower in patients with HA (including both patients with and without inhibitors) than in healthy controls. The percentages of both CD19+IgD−CD27+ class-switched and CD19+IgD+CD27+ non-class-switched memory B cells did not differ significantly between patients with and without inhibitors. HA patients with inhibitors had significantly higher proportions of CD19+CD27hiCD38hi plasmablasts than the control group as well as the inhibitor (-) ones. No significant correlation was observed between the inhibitor levels with the percentages of memory B cell subsets and plasmablasts.
Conclusion
This study is the first to demonstrate a dysregulated proportion of CD19+IgD+CD27+ non-class-switched memory B cells and CD19+CD27hiCD38hi plasmablasts in patients with severe HA. Therefore, strategies targeting memory B-cell/plasmablast differentiation may have promising outcomes in the management of inhibitor formation in patients with severe HA.